William J. Gradishar, MD, FASCO FACP, Feinberg School of Medicine in Chicago, IL, discusses ongoing and upcoming trials exploring potential changes in endocrine therapy for hormone-sensitive breast cancer patients. These trials may involve modifying therapy based on molecular factors or circulating tumor DNA (ctDNA), even in the absence of metastatic disease. In the metastatic setting, changing therapy based on ctDNA has shown promise in delaying disease progression. Similar strategies are being investigated for early-stage hormone-sensitive breast cancer. While data for clinical implementation is lacking, these trials offer potential avenues for optimizing treatment strategies. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
